Advanced Search

Study Preview



Study Title and Description

Consumption of the Soluble Dietary Fibre Complex PolyGlycopleX(®) Reduces Glycaemia and Increases Satiety of a Standard Meal Postprandially.



Key Questions Addressed
1 Is this an intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Consumption of the Soluble Dietary Fibre Complex PolyGlycopleX(®) Reduces Glycaemia and Increases Satiety of a Standard Meal Postprandially.
Author Solah VA., O'Mara-Wallace B., Meng X., Gahler RJ., Kerr DA., James AP., Fenton HK., Johnson SK., Wood S.
Country School of Public Health, Faculty of Health Sciences, Curtin University, Perth, Western Australia 6845, Australia. v.solah@curtin.edu.au.
Year 2016
Numbers Pubmed ID: 27164135

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber 4.1
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
pubyear 2016
  • Comments Comments (
    0
    ) |
country Australia
  • Comments Comments (
    0
    ) |
design Randomized Controlled Trial (Crossover)
  • Comments Comments (
    0
    ) |
blindness PGX and WD arm double-blinded. The third arm, PGX softgel was single-blinded
  • Comments Comments (
    0
    ) |
diet Acute Feeding Study
  • Comments Comments (
    0
    ) |
feedcontrol All food provided (metabolic study)
  • Comments Comments (
    0
    ) |
sampsize 14
  • Comments Comments (
    0
    ) |
runin No
  • Comments Comments (
    0
    ) |
washout Yes
  • Comments Comments (
    0
    ) |
dosechange Yes
  • Comments Comments (
    0
    ) |
age_adult 1
  • Comments Comments (
    0
    ) |
age_adol 1
  • Comments Comments (
    0
    ) |
age_child
  • Comments Comments (
    0
    ) |
age_baby
  • Comments Comments (
    0
    ) |
age_infant
  • Comments Comments (
    0
    ) |
age_oth
  • Comments Comments (
    0
    ) |
age_mean 21.9
  • Comments Comments (
    0
    ) |
age_range 19-32
  • Comments Comments (
    0
    ) |
bmi_mean 23.2
  • Comments Comments (
    0
    ) |
bmi_range 19-32
  • Comments Comments (
    0
    ) |
blhealth_healthy 1
  • Comments Comments (
    0
    ) |
blhealth_hyperlip
  • Comments Comments (
    0
    ) |
blhealth_diab
  • Comments Comments (
    0
    ) |
blhealth_hyperten
  • Comments Comments (
    0
    ) |
blhealth_digest
  • Comments Comments (
    0
    ) |
blhealth_met
  • Comments Comments (
    0
    ) |
blhealth_oth
  • Comments Comments (
    0
    ) |
blhealth_othspec
  • Comments Comments (
    0
    ) |
gender ~14
  • Comments Comments (
    0
    ) |
ftype1 PolyGlycopleX (PGX)
  • Comments Comments (
    0
    ) |
descrip1_1
  • Comments Comments (
    0
    ) |
descrip1_2
  • Comments Comments (
    0
    ) |
dose1_1 5
  • Comments Comments (
    0
    ) |
dose1_2
  • Comments Comments (
    0
    ) |
duration1
  • Comments Comments (
    0
    ) |
admin1 Powder
  • Comments Comments (
    0
    ) |
ftype2 Wheat dextrin
  • Comments Comments (
    0
    ) |
descrip2_1
  • Comments Comments (
    0
    ) |
descrip2_2
  • Comments Comments (
    0
    ) |
dose2_1 5
  • Comments Comments (
    0
    ) |
dose2_2
  • Comments Comments (
    0
    ) |
duration2
  • Comments Comments (
    0
    ) |
admin2 Powder
  • Comments Comments (
    0
    ) |
ftype3
  • Comments Comments (
    0
    ) |
descrip3_1
  • Comments Comments (
    0
    ) |
descrip3_2
  • Comments Comments (
    0
    ) |
dose3_1
  • Comments Comments (
    0
    ) |
dose3_2
  • Comments Comments (
    0
    ) |
duration3
  • Comments Comments (
    0
    ) |
admin3
  • Comments Comments (
    0
    ) |
ftype4
  • Comments Comments (
    0
    ) |
descrip4_1
  • Comments Comments (
    0
    ) |
descrip4_2
  • Comments Comments (
    0
    ) |
dose4_1
  • Comments Comments (
    0
    ) |
dose4_2
  • Comments Comments (
    0
    ) |
duration4
  • Comments Comments (
    0
    ) |
admin4
  • Comments Comments (
    0
    ) |
comparator1 PGX soft gel
  • Comments Comments (
    0
    ) |
cdose1 4.5
  • Comments Comments (
    0
    ) |
cduration1
  • Comments Comments (
    0
    ) |
cadmin1 Tablet
  • Comments Comments (
    0
    ) |
comparator2
  • Comments Comments (
    0
    ) |
cdose2
  • Comments Comments (
    0
    ) |
cduration2
  • Comments Comments (
    0
    ) |
cadmin2
  • Comments Comments (
    0
    ) |
comparator3
  • Comments Comments (
    0
    ) |
cdose3
  • Comments Comments (
    0
    ) |
cduration3
  • Comments Comments (
    0
    ) |
cadmin3
  • Comments Comments (
    0
    ) |
comparator4
  • Comments Comments (
    0
    ) |
cdose4
  • Comments Comments (
    0
    ) |
cduration4
  • Comments Comments (
    0
    ) |
cadmin4
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.